Asset Details
Do you wish to reserve the book?
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
Do you wish to request the book?
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa
2003
Overview
Until the recent introduction of imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0·54, 95% Cl 0·31–0·93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0·13, 0·05–0·39), those with no cytogenetic response to imatinib had significantly worse survival (1·69, 1·09–2·64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.
Publisher
Elsevier Ltd,Lancet,Elsevier Limited
Subject
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Councils
/ Female
/ Humans
/ Imatinib
/ Interferon-alpha - therapeutic use
/ Leukemia
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy
/ Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
/ Male
/ Patients
/ Pharmacology. Drug treatments
/ Piperazines - therapeutic use
/ Pyrimidines - therapeutic use
/ Survival
